businesswire.com/news/home/...
There is a bit of good news for RRMS people in that there is new data showing Ocrevus significantly prevented progression over Rebif when measured by a new measurement (PIRA).
Personally, I take this news with a grain of salt because it would be more useful to me to see data measuring Ocrevus against a tier 2 or tier 3 DMT not a tier 1 interferon. I'm still concerned about switching from Tysabri to Ocrevus when this has not been studied at all.